Using peripheral blood samples from CheckMate-067 (CM-067)2, a phase III MM clinical trial with extensive annotated clinical information, we assessed if response to anti-CTLA-4 (ipilimumab; IPI), anti-PD-1 (nivolumab; NIVO) and their combination (IPI-NIVO or COMBO) differs by MT-HG status. The gene discussed is CTLA4; the disease is Miyoshi myopathy.